Nuvalent (NASDAQ:NUVL) Rating Increased to Hold at Guggenheim

Guggenheim upgraded shares of Nuvalent (NASDAQ:NUVL) to a hold rating in a research note published on Wednesday,Zacks.com reports.

A number of other research firms have also commented on NUVL. HC Wainwright lowered shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price objective on the stock. in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Cantor Fitzgerald downgraded shares of Nuvalent from an “overweight” rating to a “neutral” rating in a report on Tuesday. Leerink Partners set a $165.00 target price on shares of Nuvalent in a report on Wednesday, June 3rd. Finally, Raymond James Financial downgraded shares of Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $131.15.

Nuvalent Stock Performance

NASDAQ NUVL opened at $123.35 on Wednesday. The firm has a market cap of $9.74 billion, a PE ratio of -20.35 and a beta of 1.15. Nuvalent has a one year low of $71.13 and a one year high of $123.62. The firm’s fifty day moving average is $103.44 and its two-hundred day moving average is $103.19.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the prior year, the business posted ($1.18) EPS. Research analysts predict that Nuvalent will post -5.74 earnings per share for the current year.

Insider Activity

In related news, insider Henry E. Pelish sold 3,093 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Deborah Ann Miller sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $107.84, for a total transaction of $593,120.00. Following the sale, the insider directly owned 59,634 shares in the company, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 126,953 shares of company stock worth $12,612,264 in the last ninety days. 5.02% of the stock is currently owned by insiders.

Institutional Trading of Nuvalent

A number of institutional investors have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC boosted its holdings in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after buying an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent during the third quarter worth about $38,000. NBC Securities Inc. purchased a new stake in Nuvalent during the fourth quarter worth about $125,000. Finally, KBC Group NV boosted its holdings in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after buying an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent News Summary

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.